Table 1.
Challenge results, time from challenge to abnormal clinical signs, and time to death for each animal
| Group and animalb | Gender | Wt (kg) | Estimated inhaled dosage (LD50 equivalents) | Time (h) toa: |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SIBTc | Positive PA-ECL | Positive blood culture | Abnormal white blood cell count | Abnormal neutrophil count | Abnormal N/L ratio | Treatment | Death | ||||
| Group 1 | |||||||||||
| 1 | F | 3.0 | 426 | 39.78 | 42.73 | 36.68 | 48.92 | 24.95 | 42.73 | 45.00 | NA |
| 2 | F | 3.4 | 950 | 61.52 | 48.72 | 48.72 | 36.47 | 36.47 | 48.72 | 51.00 | NA |
| 3 | M | 3.7 | 449 | 39.20 | 42.27 | 36.22 | 30.27 | 36.22 | 36.22 | 45.00 | NA |
| 4 | F | 4.3 | 386 | 60.62 | 47.45 | 47.45 | 41.22 | 50.87 | 59.42 | 51.00 | NA |
| 5 | M | 3.3 | 477 | 38.88 | 23.02 | 23.02 | 40.72 | 28.47 | 28.47 | 27.00 | NA |
| 6 | M | 3.4 | 430 | 38.18 | 27.90 | 27.9 | 52.00 | 31.18 | 40.17 | 33.00 | NA |
| 7 | M | 6.1 | 372 | 63.17 | 30.55 | 30.55 | 33.77 | 36.52 | 36.52 | 33.00 | 85.33 |
| 8 | F | 2.9 | 371 | 37.72 | 30.17 | 33.40 | 36.13 | 36.13 | 42.17 | 33.00 | NA |
| 9 | F | 3.0 | 315 | 61.07 | 41.72 | 41.72 | 65.77 | 59.60 | 59.60 | 45.00 | 84.23 |
| 10 | M | 3.4 | 369 | 37.53 | 29.20 | 23.48 | 32.32 | 35.18 | 35.18 | 33.00 | 101.93 |
| 11 | M | 4.0 | 262 | 63.93 | 52.77 | 47.12 | 55.68 | 55.68 | 71.02 | 57.00 | NA |
| 12 | F | 4.3 | 377 | 52.70 | 34.58 | 34.58 | 190.3 | 47.02 | 47.02 | 39.00 | NA |
| Group 2 | |||||||||||
| 1 | M | 5.2 | 443 | 60.92 | 42.05 | 36.05 | 54.22 | 30.10 | 36.05 | NA | 156.78 |
| 2 | M | 7.2 | 390 | 59.68 | 41.92 | 41.92 | 48.02 | 60.10 | 60.10 | NA | NA |
| 3 | F | 4.3 | 612 | 39.30 | 41.65 | 35.57 | 119.72 | 119.72 | 47.93 | NA | 173.97 |
| 4 | F | 2.9 | 678 | NA | 41.35 | 41.35 | 65.52 | 59.55 | 59.55 | NA | 93.78 |
| 5 | F | 3.1 | 601 | 37.32 | 28.82 | 23.25 | NA | NA | 47.22 | NA | 118.05 |
| 6 | M | 3.6 | 497 | 63.68 | 58.73 | 58.73 | 118.35 | 118.35 | 118.35 | NA | 220.40 |
| 7 | M | 7.3 | 198 | 36.80 | 43.03 | 43.03 | 121.13 | 121.13 | 55.08 | NA | 181.98 |
| 8 | M | 4.0 | 364 | 62.37 | 36.65 | 36.65 | 66.75 | 66.75 | 48.90 | NA | 133.57 |
| 9 | F | 3.3 | 382 | NA | 41.88 | 48.10 | 66.02 | 35.85 | 66.02 | NA | 71.12 |
| 10 | F | 2.7 | 402 | 85.20 | 28.95 | 28.95 | 65.12 | 118.82 | 58.88 | NA | 131.40 |
| 11 | M | 4.0 | 385 | 44.42 | 28.38 | 22.75 | NA | NA | NA | NA | 51.05 |
| 12 | F | 3.0 | 244 | 55.13 | 34.13 | 40.38 | 58.05 | 189.90 | 52.13 | NA | NA |
a
Time to each abnormal parameter, time to treatment, and time to death are indicated in hours postchallenge. NA, not applicable.
b
Group 1 included animals challenged with B. anthracis and treated with antibody when PA-ECL positive; group 2 included animals challenged with B. anthracis but not treated.
c
SIBT, significant increase in body temperature (six consecutive measurements above the temperature threshold).